Mickael Hiligsmann

Summary

Country: Belgium

Publications

  1. ncbi request reprint [Long-term risk of osteoporotic fracture in Belgium]
    M Hiligsmann
    Département d Economie, HEC ULg, Universite de Liege
    Rev Med Liege 63:480-7. 2008
  2. doi request reprint Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women
    Mickael Hiligsmann
    Department of Public Health, Epidemiology, and Health Economics, University of Liege, Liege, Belgium
    J Bone Miner Res 28:807-15. 2013
  3. doi request reprint The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland
    Mickael Hiligsmann
    Department of Internal Medicine, Caphri Research Institute, Maastricht University, Maastricht, The Netherlands
    Value Health 15:604-12. 2012
  4. ncbi request reprint [A changing medical and economic world: complex diseases and interest in economic evaluation of health technologies]
    M Hiligsmann
    Departement de sante publique, d Epidémiologie et d Economie de la Santé, Faculte de Medecine, Universite de Liege, Belgique
    Rev Med Liege 67:258-62. 2012
  5. doi request reprint The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis
    Mickael Hiligsmann
    Department of Internal Medicine, Division of Rheumatology and Caphri Research Institute, Maastricht University, Maastricht, P Debyelaan 25, 6229 HX Maastricht, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 12:159-66. 2012
  6. doi request reprint Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007)
    Mickael Hiligsmann
    Department of Public Health Sciences, University of Liege, Avenue de l hôpital 3, Liege, Belgium
    Arthritis Care Res (Hoboken) 64:744-50. 2012
  7. ncbi request reprint Potential clinical and economic impact of nonadherence with osteoporosis medications
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Boulevard du Rectorat 7, Bât B31, 4000 Liege, Belgium
    Calcif Tissue Int 86:202-10. 2010
  8. doi request reprint Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Liege, Belgium
    Bone 47:34-40. 2010
  9. doi request reprint Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
    Mickael Hiligsmann
    Pharmacoeconomics Unit Research, HEC School of Management, University of Liege, Avenue de l hôpital 3, Bat B23, 4000 Liege, Belgium
    Expert Rev Pharmacoecon Outcomes Res 10:359-66. 2010
  10. doi request reprint Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium
    Mickael Hiligsmann
    Pharmacoeconomics Research Unit, University of Liege, Belgium
    Pharmacoeconomics 29:895-911. 2011

Detail Information

Publications27

  1. ncbi request reprint [Long-term risk of osteoporotic fracture in Belgium]
    M Hiligsmann
    Département d Economie, HEC ULg, Universite de Liege
    Rev Med Liege 63:480-7. 2008
    ..9% and 14.8% and for osteoporotic women 32.3% and 53.4%. Our lifetime risk estimates re-emphasize that osteoporosis is a major public health problem and that its societal burden is likely to increase due to demographic changes...
  2. doi request reprint Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women
    Mickael Hiligsmann
    Department of Public Health, Epidemiology, and Health Economics, University of Liege, Liege, Belgium
    J Bone Miner Res 28:807-15. 2013
    ....
  3. doi request reprint The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland
    Mickael Hiligsmann
    Department of Internal Medicine, Caphri Research Institute, Maastricht University, Maastricht, The Netherlands
    Value Health 15:604-12. 2012
    ..This study aimed to quantify the clinical and economic impacts of poor adherence and to evaluate the potential cost-effectiveness of improving patient adherence by using hypothetical behavioral interventions...
  4. ncbi request reprint [A changing medical and economic world: complex diseases and interest in economic evaluation of health technologies]
    M Hiligsmann
    Departement de sante publique, d Epidémiologie et d Economie de la Santé, Faculte de Medecine, Universite de Liege, Belgique
    Rev Med Liege 67:258-62. 2012
    ..This article introduces the methods for the economic evaluation of health care programs and discusses the challenges of using economic evaluation in medical decision making...
  5. doi request reprint The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis
    Mickael Hiligsmann
    Department of Internal Medicine, Division of Rheumatology and Caphri Research Institute, Maastricht University, Maastricht, P Debyelaan 25, 6229 HX Maastricht, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 12:159-66. 2012
    ..Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges...
  6. doi request reprint Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007)
    Mickael Hiligsmann
    Department of Public Health Sciences, University of Liege, Avenue de l hôpital 3, Liege, Belgium
    Arthritis Care Res (Hoboken) 64:744-50. 2012
    ..To examine the secular trend of hip fracture incidence in Belgium between 2000 and 2007 and the concomitant change in the prescriptions of antiosteoporosis medications...
  7. ncbi request reprint Potential clinical and economic impact of nonadherence with osteoporosis medications
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Boulevard du Rectorat 7, Bât B31, 4000 Liege, Belgium
    Calcif Tissue Int 86:202-10. 2010
    ..Adherence therefore remains an important challenge for health-care professionals treating osteoporosis...
  8. doi request reprint Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Liege, Belgium
    Bone 47:34-40. 2010
    ..5 or prevalent vertebral fracture, aged 60 years and above. Additional data are needed on the relative cost-effectiveness compared with other anti-osteoporotic agents and on the long-term safety of denosumab...
  9. doi request reprint Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
    Mickael Hiligsmann
    Pharmacoeconomics Unit Research, HEC School of Management, University of Liege, Avenue de l hôpital 3, Bat B23, 4000 Liege, Belgium
    Expert Rev Pharmacoecon Outcomes Res 10:359-66. 2010
    ..Further analyses are required to assess the effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men...
  10. doi request reprint Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium
    Mickael Hiligsmann
    Pharmacoeconomics Research Unit, University of Liege, Belgium
    Pharmacoeconomics 29:895-911. 2011
    ..However, further studies would be required to evaluate the long-term safety and adherence of denosumab in real-world clinical practice as well as head-to-head effectiveness compared with oral bisphosphonates...
  11. doi request reprint Utility values associated with osteoporotic fracture: a systematic review of the literature
    Mickael Hiligsmann
    Department of Epidemiology, Public Health, and Health Economics, University of Liege, Avenue de l Hopital, Bat B23, 4000 Liege, Belgium
    Calcif Tissue Int 82:288-92. 2008
    ..Although we tried to determine the best available values, these values do not preclude the need for country-specific studies. Finally, we also make recommendations regarding the design and methodology for such studies...
  12. doi request reprint The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
    Mickael Hiligsmann
    HEC School of Management, Department of Economics, University of Liege, Boulevard du Rectorat 7, Liege 1, Belgium
    Health Policy 96:170-7. 2010
    ..This study aims to estimate the clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients and the potential cost-effectiveness of adherence-enhancing interventions...
  13. doi request reprint Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Liege, Belgium
    Value Health 13:394-401. 2010
    ..To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis...
  14. doi request reprint Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women
    Mickael Hiligsmann
    Department of Economics, University of Liege, Liege, Belgium
    Bone 43:991-4. 2008
    ..To estimate the lifetime absolute risks of hip and other osteoporotic fracture in Belgian women aged 60 years and to examine the effect of changes in baseline population fracture risk and changes in life expectancy...
  15. ncbi request reprint [Economic evaluation of osteoporosis screening strategy conducted in the Province of Liège with the cooperation of Liège Province Santé]
    M Hiligsmann
    Département d Economie, HEC ULg, Universite de Liege, Belgique
    Rev Med Liege 63:588-94. 2008
    ..Furthermore, to improve the efficiency of the screening strategy, we suggest to target screening on women with one or more clinical risk factors, or on women aged 65 years and older...
  16. doi request reprint Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women
    M Hiligsmann
    Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
    Osteoporos Int 21:157-65. 2010
    ..The results of this study suggested that long-term treatment with strontium ranelate over 5 years is cost-effective compared to no treatment for postmenopausal osteoporotic women...
  17. doi request reprint Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Boulevard du Rectorat 7, Bât B31, 4000 Liege, Belgium
    Bone 46:440-6. 2010
    ..To estimate the cost-effectiveness of strontium ranelate in the treatment of postmenopausal osteoporotic women aged over 75 years...
  18. doi request reprint Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis
    Mickael Hiligsmann
    Department of Economics, University of Liege, Liege, Belgium
    Value Health 12:687-96. 2009
    ..In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis...
  19. doi request reprint Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women
    Olivier Bruyere
    Department of Public Health, Epidemiology and Health Economics, University of Liege, CHU Sart Tilman, Bat B23, 4000, Liege, Belgium
    Eur J Epidemiol 24:707-12. 2009
    ..However, spine BMD changes do not influence vertebral fracture incidence...
  20. doi request reprint Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
    Mickael Hiligsmann
    Department of Health Services Research, School for Public Health and Primary Care, Maastricht University, P O Box 616, 6200 MD Maastricht, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 13:19-28. 2013
    ..In most economic evaluations, denosumab has been considered as a cost-effective treatment compared with first-line and second-line options (including generic alendronate) in the treatment of women with high risk of fractures...
  21. doi request reprint Strontium ranelate: the first agent of a new therapeutic class in osteoporosis
    Audrey Neuprez
    Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liege, Liege, Belgium
    Adv Ther 25:1235-56. 2008
    ..In conclusion, strontium ranelate has the potential to be a candidate for first-line treatment of osteopenia and osteoporosis. However, further research is needed before suggesting its widespread use in osteoarthritis...
  22. ncbi request reprint Strontium ranelate: new data on fracture prevention and mechanisms of action
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, CHU Centre Ville, Policliniques L Brull, 4020 Liege, Belgium
    Curr Osteoporos Rep 7:96-102. 2009
    ..Due to a positive risk/benefit ratio, strontium ranelate is now considered as a first-line treatment in the management of osteoporosis...
  23. ncbi request reprint [A FRAX model for the assessment of fracture probability in Belgium]
    A Neuprez
    Département des Sciences de la Santé Publique, Service de Sante Publique, épidémiologie et économie de la santé, Faculte de Medecine, Universite de Liege
    Rev Med Liege 64:612-9. 2009
    ..The approach will need to be supported by health economic analyses...
  24. doi request reprint Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis
    O Bruyere
    Department of Public Health, Epidemiology and Health Economics, University of Liege, CHU Sart Tilman, Liege, Belgium
    J Med Econ 12:356-60. 2009
    ..The second objective was, using these data, to conduct economic analyses...
  25. pmc Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis
    Mickael Hiligsmann
    Department of Health Services Research, School for Public Health and Primary Care CAPHRI, Maastricht University, The Netherlands
    Patient Prefer Adherence 7:133-9. 2013
    ..This study aims to test the feasibility of using the nominal group technique (NGT) to select attributes for DCEs...
  26. pmc Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis
    Jean Yves Reginster
    Department of Public Health Sciences, University of Liege, Liege, Belgium
    Ther Adv Musculoskelet Dis 2:133-43. 2010
    ..Owing to a positive benefit/risk ratio, strontium ranelate may now be considered as a first-line treatment in the management of osteoporosis...
  27. pmc Health technology assessment in osteoporosis
    Mickael Hiligsmann
    Department of Health Services Research, School for Public Health and Primary Care CAPHRI, Maastricht University, P O Box 616, Maastricht, 6200 MD, The Netherlands
    Calcif Tissue Int 93:1-14. 2013
    ..In summary, health technology assessment is increasingly used in the field of osteoporosis and could be very useful to help decision makers efficiently allocate health-care resources...